Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 54 min ago
PreprintCC BY-NC-NDmedRxiv

Delayed-centrifugation blood collection tube for remote blood biomarker assessment

  1. 1University of Pittsburgh

Abstract

Introduction: Plasma phosphorylated tau 217 (p-tau217) and amyloid-{beta} 42 (A{beta}42) are advancing toward clinical use for Alzheimer's disease (AD), but their reliability can be impacted by preanalytical handling. Although alternative collection tubes with distinct stabilization strategies --P100 (protease inhibitor) and HEMAcollect (hemolysis/platelet-activation minimization) --have been developed to stabilize plasma proteins, how well they preserve these markers remains unresolved; we therefore compared both against fresh standard EDTA tubes. Methods: In 40 participants, plasma p-tau217 and A{beta}42 were measured (Lumipulse) in paired fresh EDTA, P100, and HEMAcollect samples after 5-day ambient storage. We assessed concentration change, rank-order preservation (Spearman {rho}), percentage difference, and diagnostic classification under the p-tau217/A{beta}42 ratio and p-tau217 alone. Results: P100 preserved p-tau217 favorably, with high rank-order correlation ({rho}=0.98) and a modest median change (+12.1%), and its classification agreement with fresh EDTA reached 97.5% using p-tau217 alone. HEMAcollect showed greater p-tau217 signal loss (-57.5%). A{beta}42 was reduced in both tubes (-72.8% P100; -95.5% HEMAcollect) with loss of rank order, so neither preserved the p-tau217/A{beta}42 ratio. Discussion: Stability was tube- and analyte-specific, and P100 consistently outperformed HEMAcollect --preserving p-tau217 rank order while HEMAcollect reduced signal across analytes. Although neither tube preserved the A{beta}42-dependent ratio, P100 shows potential for p-tau217-based workflows. Preanalytical stability must be established analyte by analyte before alternative tubes enter clinical AD diagnosis.

Related

  1. Analytical performance of a delayed-centrifugation blood collection tube for remote blood biomarker assessment
    Y.-R. Lee, X. Zeng, M. F. Farinas +4
    medRxivPreprintCC BY-NC-NDFull textNeurologymedRxiv
  2. Performance Assessment of Centrifugation-Based Hematocrit Testing in Primary Care Units: Evidence from Seventy-Two Proficiency Testing Datasets over Eight Years
    Watcharinthon Theansun, Kunchit Kongros, Napaporn Apiratmateekul +5
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Fluoroscopy-Guided Colonoscopic Transanastomotic Drainage of a Delayed Presacral Collection After Rectal Cancer Surgery: A Case Report
    Mehdi Zouaoui, Mohamed Aymane Assili, Youssef Hnach +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. A Narrative Review of Remote Biospecimen Collection Product and Implementation Considerations for Sexual Health Clinical Research
    Keith J. Horvath, Sarah E. Rutstein, Ryan P. Coyle +11
    AIDS and behaviorPeer-reviewedCC BY-NC-ND 4.0Full textInfectious diseasePMC
  5. Effect of delayed remote ischemic preconditioning on major cardiovascular and cerebrovascular events in major vascular surgery: the protocol of DRIPC randomized controlled trial
    Linyao Zhu, Min Li, Jichun Zhao +6
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Full textCardiovascular medicineCrossrefEurope PMC
BibTeX
@misc{lee2026delayedcentrifugation,
  title = {{Delayed-centrifugation blood collection tube for remote blood biomarker assessment}},
  author = {Y.-R. Lee and A. Raj and O. Lopez and X. Zeng and T. K. Karikari},
  howpublished = {medRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.30.26366958},
  url = {https://www.medrxiv.org/content/10.64898/2026.10.30.26366958v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - UNPB
TI  - Delayed-centrifugation blood collection tube for remote blood biomarker assessment
AU  - Y.-R. Lee
AU  - A. Raj
AU  - O. Lopez
AU  - X. Zeng
AU  - T. K. Karikari
PY  - 2026
DA  - 2026/10/30
PB  - medRxiv
DO  - 10.64898/2026.10.30.26366958
UR  - https://www.medrxiv.org/content/10.64898/2026.10.30.26366958v1
AB  - Introduction: Plasma phosphorylated tau 217 (p-tau217) and amyloid-{beta} 42 (A{beta}42) are advancing toward clinical use for Alzheimer's disease (AD), but their reliability can be impacted by preanalytical handling. Although alternative collection tubes with distinct stabilization strategies --P100 (protease inhibitor) and HEMAcollect (hemolysis/platelet-activation minimization) --have been developed to stabilize plasma proteins, how well they preserve these markers remains unresolved; we therefore compared both against fresh standard EDTA tubes. Methods: In 40 participants, plasma p-tau217 and A{beta}42 were measured (Lumipulse) in paired fresh EDTA, P100, and HEMAcollect samples after 5-day ambient storage. We assessed concentration change, rank-order preservation (Spearman {rho}), percentage difference, and diagnostic classification under the p-tau217/A{beta}42 ratio and p-tau217 alone. Results: P100 preserved p-tau217 favorably, with high rank-order correlation ({rho}=0.98) and a modest median change (+12.1%), and its classification agreement with fresh EDTA reached 97.5% using p-tau217 alone. HEMAcollect showed greater p-tau217 signal loss (-57.5%). A{beta}42 was reduced in both tubes (-72.8% P100; -95.5% HEMAcollect) with loss of rank order, so neither preserved the p-tau217/A{beta}42 ratio. Discussion: Stability was tube- and analyte-specific, and P100 consistently outperformed HEMAcollect --preserving p-tau217 rank order while HEMAcollect reduced signal across analytes. Although neither tube preserved the A{beta}42-dependent ratio, P100 shows potential for p-tau217-based workflows. Preanalytical stability must be established analyte by analyte before alternative tubes enter clinical AD diagnosis.
ER  -